In Section A, contributors will receive diverse doses and schedules of oral ABBV-744 pill to determine Harmless dosing regimen. Added contributors will likely be enrolled for the identified monotherapy dosign regimen. In Segment B, individuals will get oral ruxolitinib and ABBV-744 will be presented as "increase-on" therapy. In Phase C, https://abbv-744-preclinical-stud35780.qodsblog.com/31973350/a-simple-key-for-abbv-744-brd4-inhibition-in-cancer-cell-lines-unveiled